Registered Kenya · PPB

PHARMAXOLOL EYE DROPS

BETAXOLOL HYDROCHLORIDE

H2020/CTD7911/1401ER 0.5%W/V GENERIC/BIOSIMILARS cardiovascular system INN generic

What it does

Betaxolol is a medication used to manage certain heart conditions.

Commonly used for: high blood pressure (hypertension), glaucoma

Read more in plain English ↓

Plain-language summary for general understanding - not medical advice. Always follow your pharmacist/doctor.

Ask about this medicine

Answers come only from this medicine's registration record, BNF monograph and interaction data - not medical advice.

Hard to find? We help patients in Kenya source rare medicines. We don't sell or dispense medicines - licensed pharmacies do.

Source this medicine

Registration & product details

Registration no.
H2020/CTD7911/1401ER
Registration date
2020-04-17 00:00:00
Expiry date
-
Status
Registered
Active ingredient
BETAXOLOL HYDROCHLORIDE
Dosage form
0.5%W/V
Strength
-
Pack size
5ML
Therapeutic class
GENERIC/BIOSIMILARS
ATC class (WHO)
C07AB - Beta blocking agents, selective
RxNorm RxCUI
1520
Manufacturer / MAH
Ivee Aqua
Applicant / LTR
IVEE AQUA EPZ LTD
Country of origin
LOCAL
Manufacturer location
Epz, Athi River, Kenya

Source: Pharmacy and Poisons Board · fetched 2026-01-28 19:52:17 · updated 2026-08-03 03:01:25

Drug Interactions

1
Check interactions

Pharmacodynamic Warnings

Betaxolol appears in TABLE 6: Drugs that cause bradycardia

Betaxolol appears in TABLE 8: Drugs that cause hypotension

Moderate (1)

Betaxolol - increases risk of cardiovascular adverse effects

Propafenoneispredictedtoincreasetheriskofcardiovascular adverseeffectswhengivenwithbetablockers,selective (acebutolol,atenolol,betaxolol,bisoprolol,celiprolol,esmolol). Usewithcautionoravoid.rStudy →A

Moderate Study

Data from BNF 85 (British National Formulary). This is not a substitute for professional medical advice. Matched via: exact

Disclaimer: This information is sourced from Pharmacy and Poisons Board (Kenya). Always consult a qualified healthcare professional before using any medication.

About this medicine

Betaxolol is a medication used to manage certain heart conditions.

What it treats

  • high blood pressure (hypertension)
  • glaucoma

How it works

Betaxolol helps lower blood pressure and reduces eye pressure by blocking certain receptors in the heart and eyes.

Who it's for

It is prescribed for adults with high blood pressure or glaucoma.

Cautions

  • • Be cautious if you are taking other medications that slow your heart rate.
  • • Be careful if you are using medications that lower blood pressure.

AI-assisted summary grounded in BNF data - general information only, not medical advice. Always confirm with your pharmacist or doctor.

Clinical monograph: Betaxolol

BNF-referenced

Betaxolol is a selective beta-1 adrenergic antagonist used primarily in the management of glaucoma and ocular hypertension by reducing intraocular pressure.

Indications

  • Primary glaucoma
  • Secondary glaucoma
  • Ocular hypertension

Dosage

Children: Apply 1-2 times a day; refer to BNF for Children for specific dosing guidance.

Adults: Instill 1 drop into the affected eye(s) once or twice daily.

Mechanism of action

Betaxolol works by selectively blocking beta-1 adrenergic receptors in the ciliary body, leading to decreased production of aqueous humor, thereby lowering intraocular pressure.

Pharmacodynamics

The drug exhibits a dose-dependent reduction in intraocular pressure, making it effective in both primary and secondary glaucomas. Its selectivity for beta-1 receptors provides a lower risk of systemic side effects compared to non-selective beta blockers.

Pharmacokinetics

Betaxolol is absorbed topically, with systemic absorption being possible. It undergoes hepatic metabolism and has a half-life that allows for twice-daily dosing. The distribution and elimination characteristics are similar to other beta-blockers, but specific details on its pharmacokinetics are limited.

Contra-indications

  • bradycardia
  • heart block

Adverse effects

  • eye discomfort
  • eye inflammation
  • dry eye
  • blurred vision

Interactions

  • propafenone: Moderate (increases risk of cardiovascular adverse effects)

Precautions

  • Patients with corneal disease
  • Systemic absorption can occur following topical application

Pregnancy

Refer to specific guidelines; consult healthcare provider.

Breast-feeding

Refer to specific guidelines; consult healthcare provider.

Storage

Store at room temperature, away from light. Do not freeze.

Formulations

  • Betoptic 0.25% suspension eye drops | 5 ml
  • Betoptic 0.25% eye drops suspension 0.25ml unit dose | 50 unit
BNF for Children 2019-2020 p.728 PubChem / pathway

AI-synthesized from BNF references - general information only, not a substitute for professional medical advice or the current BNF. Verify doses with a pharmacist.

Molecular reference: Betaxolol

PubChem CID 2369

Molecular formula: C18H29NO3

Mechanism of action

Betaxolol selectively blocks catecholamine stimulation of beta(1)-adrenergic receptors in the heart and vascular smooth muscle. This results in a reduction of heart rate, cardiac output, systolic and diastolic blood pressure, and possibly reflex orthostatic hypotension. Betaxolol can also competitively block beta(2)-adrenergic responses in the bronchial and vascular smooth muscles, causing bronchospasm.

Pharmacodynamics

Betaxolol is a competitive, beta(1)-selective (cardioselective) adrenergic antagonist. Betaxolol is used to treat hypertension, arrhythmias, coronary heart disease, glaucoma, and is also used to reduce non-fatal cardiac events in patients with heart failure. Activation of beta(1)-receptors (located mainly in the heart) by epinephrine increases the heart rate and the blood pressure, and the heart consumes more oxygen. Drugs such as betaxolol that block these receptors therefore have the reverse effect: they lower the heart rate and blood pressure and hence are used in conditions when the heart itself is deprived of oxygen. They are routinely prescribed in patients with ischemic heart disease. In addition, beta(1)-selective blockers prevent the release of renin, which is a hormone produced by the kidneys which leads to constriction of blood vessels. Betaxolol is lipophilic and exhibits no intrinsic sympathomimetic activity (ISA) or membrane stabilizing activity.

Source: PubChem (NCBI) · pathways from PathBank, Reactome, WikiPathways & PharmGKB.

This drug in other countries

The same active ingredient registered across other registries we cover - including different brands.